At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
About Us

The Dr. Sol J. Barer Award for
Vision, Innovation and Leadership
Loading the player ...

RareVoice Lifetime Achievement Award – Rare Disease Congressional Caucus Briefing
Home >> About Us >> Overview

Company Profile

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company has a robust development pipeline of novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new therapies to individuals with lysosomal storage disorders (LSDs).

Amicus is building a leading fully-integrated company in the area of rare diseases. The Company’s lead product candidate, migalastat, is a small molecule in development for Fabry disease, both as a monotherapy and in combination with enzyme replacement therapy (ERT). The Company is also leveraging its biologics and Chaperone-Advanced Replacement Therapy (CHART™) platform technologies to develop next-generation ERT products. Its lead biologics program is ATB200, a uniquely-engineered, next-generation Pompe ERT. Amicus is applying its CHART platform to combine ATB200 with a pharmacological chaperone to stabilize the administered enzyme in blood and potentially improve ERT tolerability and efficacy. Utilizing its biologics and CHART technologies, Amicus is also developing next-generation treatments for Fabry and MPS 1 with the potential to expand its pipeline into other LSDs.
Amicus Therapeutics is committed to improving the lives of patients and families affected by rare and orphan diseases.

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy